|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Tikcro Technologies Reports 2011 Fourth Quarter and Full Year Results
3/1/2012 8:22:57 AM
TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and year ended December 31, 2011.
Net loss for the fourth quarter was $0.3 million or $(0.04) per diluted share. Results for the fourth quarter included financial expenses of approximately $0.25 million that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Excluding this non-cash financial expense, net loss for the fourth quarter was $53,000 or $(0.01) per diluted share. Net loss for year ended December 31, 2011 was $2.8 million or $(0.32) per diluted share. Results for year ended December 31, 2011 included a financial expense of approximately $2.5 million from the valuation of Tikcro's holdings in BioCancell. Excluding this non-cash financial expense, net loss for the year ended December 31, 2011 was $260,000 or $(0.03) per diluted share.
|
|
|
|
|
|
|
|
|
|
|